Home Cart Sign in  
Chemical Structure| 79338-84-4 Chemical Structure| 79338-84-4

Structure of Tapinarof
CAS No.: 79338-84-4

Chemical Structure| 79338-84-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tapinarof is an aryl hydrocarbon receptor (AhR) agonist that alleviates skin inflammation in mice, potentially useful in skin disease research.

Synonyms: WBI-1001; Benvitimod; 3,5-DH4IS

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tapinarof

CAS No. :79338-84-4
Formula : C17H18O2
M.W : 254.32
SMILES Code : OC1=CC(/C=C/C2=CC=CC=C2)=CC(O)=C1C(C)C
Synonyms :
WBI-1001; Benvitimod; 3,5-DH4IS
MDL No. :MFCD13193203
InChI Key :ZISJNXNHJRQYJO-CMDGGOBGSA-N
Pubchem ID :6439522

Safety of Tapinarof

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
3D cultured NHEKs 500 nM 48 h Tapinarof increases IL-37 protein levels and decreases IL-33 protein levels PMC9161696
CD4+ T cells 1µM Tapinarof reduced Th17 cells and inhibited IL-17 secretion, while increasing Foxp3+ Treg cells. PMC11649266
mouse bone marrow-derived dendritic cells (BMDCs) 1, 3 µM Tapinarof significantly reduced the expression of IL-6 and IL-10, and decreased IL-23p19 expression. PMC11649266
human monocyte-derived dendritic cells (MoDCs) 1, 3, 10 µM Tapinarof dose-dependently inhibited the expression of CD40, CD80, and HLA-DR, and suppressed the production of IL-6, IL-12, IL-23p19, and IFN-γ. PMC11649266
Normal human epidermal keratinocytes (NHEKs) 100 nM, 500 nM 48 h Tapinarof dose-dependently upregulates IL-37 expression PMC9161696
siRNA-transfected NHEKs 500 nM 72 h To validate whether Tapinarof-induced upregulation of FLG and LOR expression is AHR-dependent. Results showed that AHR knockdown abolished Tapinarof-induced upregulation of FLG and LOR mRNA and protein. PMC7764126
Normal human epidermal keratinocytes (NHEKs) 500 nM To investigate how Tapinarof upregulates FLG and LOR expression via AHR activation. Results showed that Tapinarof upregulated FLG and LOR mRNA and protein expression in a dose-dependent manner. PMC7764126

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice IMQ-induced psoriasis model Topical application 1% tapinarof cream Tapinarof ameliorated psoriasis symptoms, reduced IL-17A expression, and increased Foxp3 expression. These effects were not observed in ahr?/? mice. PMC11649266

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06103695 Psoriasis PHASE4 COMPLETED 2023-10-18 Schweiger Derm Group, East Win... More >>dsor, New Jersey, 08520, United States Less <<
NCT01098721 Psoriasis PHASE2 COMPLETED 2025-11-10 -
NCT01098734 Dermatitis, Atopic PHASE2 COMPLETED 2025-11-10 Guilford Dermatology Associate... More >>s, Surrey, British Columbia, V3R 6A7, Canada|Department of Dermatology and Skin Sciences, UBC, Vancouver, British Columbia, V5Z 4E8, Canada|Windsor Clinical Research Inc., Windsor, Ontario, N8W 6A7, Canada|Innovaderm Research Inc., Montreal, Quebec, H2K 4L5, Canada|Centre de Recherche Dermatologique du Quebec, Quebec City, Quebec, G1V 4X7, Canada Less <<
NCT06561321 Palmoplantar Keratoderma PHASE2 RECRUITING 2026-11-01 Indiana University Department ... More >>of Dermatology, Indianapolis, Indiana, 46202, United States Less <<
NCT06661213 Cutaneous Lupus Erythematosus EARLY_PHASE1 NOT_YET_RECRUITING 2025-03-26 Northwestern University Depart... More >>ment of Dermatology, Chicago, Illinois, 60611, United States Less <<
NCT00837551 Dermatitis, Atopic PHASE1|PHASE2 COMPLETED 2025-10-08 Innovaderm Research Inc.,, Mon... More >>treal, Quebec, H2K 4L5, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.93mL

0.79mL

0.39mL

19.66mL

3.93mL

1.97mL

39.32mL

7.86mL

3.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories